Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2024 | Implications of the ICTAN trial of icotinib for resected EGFR-mutated stage II-IIIA NSCLC

Si-Yu Wang, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, discusses the implications of findings from the ICTAN trial (NCT01996098) of adjuvant icotinib following adjuvant chemotherapy for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (NSCLC). Adjuvant chemotherapies are associated with a 60% reduction in the risk of disease recurrence and Dr Wang argues these therapies are necessary for EGFR-mutated NSCLC after complete resection. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.